← Eichor
Study identifier: NCT06767150 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

Condition: Postmenopausal Osteoporosis  ·  Sponsor: University Hospital, Toulouse

PhasePhase 4
Planned participants200
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.

This description comes directly from the study's public registry record.

Talk to the study team

Yannick DEGBOE, MD  ·  05 61 77 73 75  ·  degboe.y@chu-toulouse.fr

Charline DAGUZAN  ·  05 61 77 84 90  ·  daguzan.c@chu-toulouse.fr

Always discuss trial participation with your own doctor first.

Locations (17)

Amiens HospitalAmiens, FranceRecruiting
Bordeaux HospitalBordeaux, FranceRecruiting
Cahors HospitalCahors, FranceRecruiting
Dax HospitalDax, FranceRecruiting
Le Mans HospitalLe Mans, FranceRecruiting
Lille HospitalLille, FranceNot Yet Recruiting
Limoges HospitalLimoges, FranceRecruiting
Marseille HsopitalMarseille, FranceRecruiting
Montpellier HospitalMontpellier, FranceRecruiting
Nice HospitalNice, FranceRecruiting
Orléans HospitalOrléans, FranceRecruiting
Cochin HospitalParis, FranceRecruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06767150